Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash & Equivalents (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Cash & Equivalents for 7 consecutive years, with $60.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 59.66% to $60.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60.2 million through Dec 2025, down 59.66% year-over-year, with the annual reading at $60.2 million for FY2025, 59.66% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $60.2 million at 4D Molecular Therapeutics, up from $48.6 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $275.7 million in Q3 2023, with the low at $48.6 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $152.9 million, with a median of $141.4 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents soared 375.84% in 2023, then plummeted 74.11% in 2025.
  • Over 5 years, Cash & Equivalents stood at $153.0 million in 2021, then plummeted by 65.78% to $52.4 million in 2022, then surged by 375.84% to $249.1 million in 2023, then crashed by 40.05% to $149.3 million in 2024, then tumbled by 59.66% to $60.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $60.2 million, $48.6 million, and $77.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.